Role of limited whole-body PET/CT in pediatric lymphoma

AJR Am J Roentgenol. 2011 May;196(5):1047-55. doi: 10.2214/AJR.10.6074.


Objective: Performing true whole-body FDG PET/CT is standard practice in pediatric lymphoma staging and follow-up. In adults, imaging is typically limited whole-body PET/CT, which has advantages over true whole-body PET/CT, primarily decreased scanning time and decreased radiation. We hypothesize that in pediatric lymphoma, limited whole-body PET/CT is sufficient for routine follow-up when disease on the true whole-body staging study is confined to the limited whole-body field of view (FOV).

Materials and methods: True whole-body PET/CT studies performed for staging and follow-up of pediatric lymphoma patients between November 2004 and July 2009 at two tertiary pediatric referral hospitals were retrospectively reviewed. Abnormalities on the limited whole-body and additional true whole-body FOV were documented.

Results: One hundred seventy patients met the inclusion criteria (752 examinations). At staging, disease involved the limited whole-body FOV without involving the additional true whole-body FOV in 150. Of the 150, 145 had routine follow-up (508 examinations). In these patients, no new (18)F-FDG-avid disease was identified outside of the limited whole-body FOV on routine follow-up (positive predictive value, 0%, 95% CI, 0-0.02).

Conclusion: The limited whole-body PET/CT for routine follow-up when disease is confined to the limited whole-body FOV at staging is appropriate. Given its definite advantages over true whole-body PET/CT, it is preferred.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Fluorodeoxyglucose F18
  • Follow-Up Studies
  • Humans
  • Lymphoma / diagnosis*
  • Male
  • Neoplasm Staging
  • Positron-Emission Tomography*
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Retrospective Studies
  • Tomography, X-Ray Computed*
  • Whole Body Imaging*
  • Young Adult


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18